Pleural mesothelioma is a rare but aggressive cancer that forms in the thin lining surrounding the lungs. It is caused almost exclusively by exposure to asbestos, often through occupational or military service. Most patients are diagnosed decades after their exposure—typically in their 60s or 70s—when symptoms like chest pain, persistent cough, or shortness of breath begin to interfere with daily life.
Until recently, treatment options were limited and largely palliative. But in the last few years, the outlook has begun to shift. New immunotherapy regimens, refinements in surgical technique, and more personalized chemotherapy combinations have improved survival for some patients. In 2025, physicians have more tools—and more data—than ever before.
This page explores the most current treatment options for pleural mesothelioma, along with the latest survival statistics and factors that influence prognosis. We also explain how patients can access treatment, including how asbestos lawsuits and trust funds can help cover the cost of care.
Prognosis For Pleural Mesothelioma in 2025
Pleural mesothelioma remains a challenging cancer to treat, and the prognosis can vary widely based on several key factors. While the average life expectancy after diagnosis is still measured in months rather than years, newer treatments are improving outcomes for some patients—especially those diagnosed early or with favorable tumor characteristics.
Median Survival by Cell Type
Histological subtype is one of the strongest predictors of survival. Different cell types respond differently to treatment and tend to progress at different rates.
Epithelioid mesothelioma (the most common form) has the best prognosis, with a median overall survival of 18–21 months in recent trials. These tumors tend to grow more slowly and respond better to both chemotherapy and immunotherapy regimens.3
Biphasic mesothelioma (a mix of epithelioid and sarcomatoid cells) shows a median survival of about 12 months. The prognosis is intermediate because the more aggressive sarcomatoid elements often drive faster progression. 1
Sarcomatoid mesothelioma is the most aggressive subtype, with median survival often below 9 months, and in some datasets as low as 4 months. These tumors are more resistant to treatment and often present at an advanced stage. 4
Other Prognostic Factors
Survival also depends on:
Stage at diagnosis: Localized disease (Stages I–II) is often amenable to aggressive treatment like surgery or multimodal therapy, with median survival ranging from 20 to 30 months, especially for patients with epithelioid tumors and good performance status. In contrast, patients diagnosed at Stage III typically have median survival of 12–18 months, and those with Stage IV disease often have survival under 12 months, depending on tumor burden, metastasis, and treatment access. 1, 3
Performance status (ECOG): The Eastern Cooperative Oncology Group (ECOG) performance status is a scale that measures a patient's level of functioning, from 0 (fully active) to 5 (deceased). Patients with lower ECOG scores—meaning they are more physically active and independent—generally tolerate treatments better and tend to live longer. This measure is commonly used to determine eligibility for surgery, chemotherapy, or immunotherapy.
Treatment access and histology-tailored care: Eligibility for surgery or immunotherapy can substantially extend life expectancy, particularly for patients with epithelioid histology or resectable disease. Access to specialized cancer centers, multidisciplinary teams, and clinical trials is also associated with better outcomes, as patients are more likely to receive guideline-based, individualized treatment plans.
Tumor biomarkers: While no single biomarker is definitive, loss of the BAP1 tumor suppressor gene is often seen in epithelioid mesothelioma and may be associated with longer survival. In contrast, high PD-L1 expression—more common in sarcomatoid and biphasic types—is linked to poorer prognosis but may predict better response to immunotherapy. 4
Long-Term Survival is Possible
Though rare, some patients survive several years with mesothelioma. These cases typically involve early-stage detection, epithelioid histology, and access to multimodal care that combines surgery, chemotherapy, and immunotherapy. A small subset of patients in recent trials experienced ongoing response to immunotherapy beyond two years, suggesting that long-term control may be possible in select cases. 4
That’s why it’s important not to give up hope. Statistics reflect population averages, not individual destinies—and every year, some patients defy the odds. If you're diagnosed with mesothelioma, there's no way to predict for certain whether you'll be one of the long-term responders. Advances in treatment, combined with your unique biology and circumstances, may open doors that statistics can't foresee. The only way to find out is to explore all your options, stay informed, and fight for the best care available.
Surgical Treatment for Pleural Mesothelioma
Surgery can play a role in treating pleural mesothelioma, particularly for patients diagnosed at earlier stages and with epithelioid tumors. The goal of surgery is not usually to cure the disease, but to remove as much tumor burden as possible, relieve symptoms, and potentially extend survival when used as part of a multimodal approach.
Common Surgical Procedures
There are two primary types of surgery for pleural mesothelioma:
Pleurectomy/Decortication (P/D): This procedure removes the pleura (the thin membrane lining the lungs) and any visible tumors, while sparing the lung itself. It is considered less invasive and has a lower risk of serious complications compared to more radical surgeries. P/D may also involve partial removal of the diaphragm or pericardium.
Extrapleural Pneumonectomy (EPP): A more aggressive procedure, EPP involves removing the affected lung, part of the diaphragm, pleura, and pericardium. Because it is so extensive, it is only considered in select patients with excellent cardiopulmonary reserve and localized disease.
Effectiveness and Survival Outcomes
Surgical outcomes vary by procedure type, patient health, and tumor subtype. In the MARS 2 trial, patients who underwent extended pleurectomy/decortication plus chemotherapy had worse survival (median 19.3 months) and lower quality of life than those who received chemotherapy alone (median 24.8 months), suggesting that the risks of surgery may outweigh the benefits in some cases. 1 However, other studies suggest that minimally invasive P/D techniques, such as video-assisted thoracoscopic surgery (VATS), may offer better recovery times and fewer complications.
Importantly, surgery alone is rarely curative. It is typically offered only as part of multimodal treatment, combined with chemotherapy and, in some cases, immunotherapy or radiation. Patients with epithelioid histology and Stage I–II disease are most likely to be considered surgical candidates.
Cost and Hospitalization of Surgical Treatments
Surgery for mesothelioma is also a significant financial burden. The average cost of a mesothelioma-related surgical hospitalization in the U.S. can exceed $60,000, with longer hospital stays and higher complication risks compared to non-surgical treatment. 2 Recovery often requires one to two weeks of inpatient care and may delay or reduce a patient’s ability to receive follow-up treatments like chemotherapy or immunotherapy.
Chemotherapy for Pleural Mesothelioma
Chemotherapy remains one of the foundational treatments for pleural mesothelioma, particularly for patients with advanced-stage disease or those not eligible for surgery. While not curative, chemotherapy can slow tumor progression, relieve symptoms, and extend survival. The most widely accepted first-line regimen is the combination of pemetrexed and cisplatin, which has become the gold standard for treating this cancer. For patients who cannot tolerate pemetrexed, alternative combinations like gemcitabine and cisplatin offer a viable second-line option.
Pemetrexed and Cisplatin: The Standard of Care
The combination of pemetrexed (an antifolate) and cisplatin (a platinum-based agent) has been extensively studied and is recommended by most major oncology guidelines. These drugs work synergistically to disrupt cancer cell replication:
Pemetrexed interferes with folate-dependent enzymes, which are crucial for a cell to make DNA and RNA—the building blocks of life. By blocking these enzymes, pemetrexed stops cancer cells from copying their genetic material, which they need in order to grow and divide. This slows the spread of the cancer and can help shrink existing tumors
Cisplatin works by damaging the DNA inside cancer cells, like punching holes in the instruction manual they need to survive. Unlike healthy cells, mesothelioma cells often can't repair this damage. As a result, the cells self-destruct, making cisplatin one of the most powerful tools in chemotherapy.
In a pivotal Phase III trial, patients treated with pemetrexed and cisplatin lived a median of 12.1 months, compared to 9.3 months with cisplatin alone—a statistically significant improvement in survival. The combination also led to better symptom control and improved quality of life measures. 3 4
This chemotherapy regimen is not only medically effective—it is also widely recognized by asbestos trust funds and legal settlements as a qualifying treatment expense. Many patients are able to recover these costs through legal claims.
Benefits of Pemetrexed + Cisplatin
Improved Survival: Extends median survival by several months compared to monotherapy. While that may sound modest, even a few extra months can be profoundly meaningful—allowing patients more time with family, the chance to pursue additional treatments, or simply enjoy life.
Symptom Relief: Helps reduce chest pain, pleural effusions, and breathing difficulties. By shrinking tumors or slowing their growth, chemotherapy can lessen the pressure on the lungs and chest cavity, helping patients breathe more easily and experience less day-to-day discomfort.
Quality of Life Gains: Shown to improve fatigue, appetite, and daily functioning. Many patients report feeling more energetic and able to engage in normal activities again—whether that’s preparing meals, walking the dog, or spending time with grandchildren.
Evidence-Backed: Thousands of patients have received this regimen, with strong clinical support and consistent outcomes. It is the most widely studied chemotherapy approach for mesothelioma, supported by decades of research and included in all major treatment guidelines worldwide.
However, not all patients can tolerate pemetrexed due to kidney function issues, low blood counts, or prior adverse reactions. In these cases, physicians may recommend other combinations—most notably gemcitabine and cisplatin.
Gemcitabine and Cisplatin: An Important Alternative
The gemcitabine–cisplatin combination offers a valuable alternative for patients who are not candidates for pemetrexed. Like the standard regimen, it combines two agents with complementary mechanisms of action:
Gemcitabine mimics nucleosides, which are the natural building blocks of DNA, and tricks cancer cells into using it during DNA replication. Once inserted, it disrupts the DNA copying process, halting cell division and triggering cell death. Because cancer cells divide more rapidly than normal cells, they are especially vulnerable to this kind of targeted disruption.
Cisplatin, again, damages the DNA structure directly, enhancing the cytotoxic effect.
While this combination is not as well studied as pemetrexed-based chemotherapy, several clinical trials have reported response rates of 12% to 48% and median survival ranging from 9.6 to 11.2 months in mesothelioma patients. 3These outcomes make it a competitive first-line or second-line choice in select populations.
Benefits of Gemcitabine + Cisplatin
Alternative for Sensitive Patients: Often used in those who cannot tolerate pemetrexed.
Tumor Shrinkage: Has shown measurable reductions in tumor size in many patients.
Symptom Control: Improves pain and respiratory function, especially in bulky disease.
Moderate Side Effect Profile: Generally manageable in older or frail individuals.
Gemcitabine is also being evaluated in maintenance therapy settings and in combination with immunotherapy in ongoing trials, which may expand its future role.
Immunotherapy for Pleural Mesothelioma
Immunotherapy has emerged as one of the most promising advances in the treatment of pleural mesothelioma, particularly for patients with unresectable or advanced-stage disease. Unlike chemotherapy, which directly targets cancer cells, immunotherapy helps the body’s immune system recognize and attack the tumor—a powerful strategy for a cancer that historically resisted most conventional treatments.
How Immunotherapy Works
Many mesothelioma tumors produce proteins that "hide" them from immune cells, allowing the cancer to grow unchecked. Immunotherapy drugs called immune checkpoint inhibitors block this hiding mechanism. By doing so, they "re-activate" the immune system, enabling it to identify mesothelioma cells as dangerous and destroy them.
The two most common targets of these drugs are:
PD-1/PD-L1: Proteins that act like brakes on immune cells; blocking them releases the brakes and restores immune attack.
CTLA-4: Another immune “off switch” that, when blocked, increases T-cell activation and tumor surveillance.
FDA-Approved First-Line Option: Nivolumab + Ipilimumab
The CheckMate 743 trial changed the treatment landscape by showing that the combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) significantly improved survival in mesothelioma patients. For patients with unresectable pleural mesothelioma, median overall survival was 18.1 months with immunotherapy, compared to 14.1 months for those receiving chemotherapy. 4
The benefits were especially notable for patients with non-epithelioid histology, a group that typically responds poorly to chemotherapy. In this group, immunotherapy nearly doubled survival compared to chemo (18.1 vs. 8.8 months). 4
Unlike chemotherapy, which works quickly but may lose effectiveness, immunotherapy can take longer to begin working—but in some patients, it leads to durable, long-term responses.
Other Promising Combinations
Several newer combinations are also showing potential in clinical trials:
Durvalumab + Chemotherapy (DREAM and PrE0505 trials): Median survival of 18.4–20.4 months, with many patients achieving tumor shrinkage or disease stability. Durvalumab is an anti–PD-L1 checkpoint inhibitor that allows immune cells to detect and attack cancer cells more effectively. When combined with chemotherapy, which kills cancer cells and releases tumor antigens, the immune system may be better “primed” to mount a response, resulting in synergistic effects.
Pembrolizumab + Chemotherapy (IND227 trial): Showed a survival benefit, especially in non-epithelioid patients, who usually have fewer treatment options. Pembrolizumab is an anti–PD-1 antibody that restores immune T-cell activity against tumors. Its benefit was most pronounced in patients with non-epithelioid mesothelioma, where standard chemotherapy has historically been less effective, suggesting that immune-based strategies may overcome resistance in harder-to-treat tumors.
Atezolizumab + Bevacizumab + Chemotherapy (BEAT-meso trial): Modest improvements in progression-free survival; still under review for broader use. Atezolizumab blocks PD-L1, while bevacizumab inhibits VEGF, a protein that helps tumors grow new blood vessels. By starving the tumor’s blood supply and simultaneously activating the immune system, this combination aims to both suppress growth and improve immune detection—but the overall survival benefit has been less clear so far.
These therapies are being explored for first-line and second-line use, depending on patient characteristics and tumor biology.
Benefits of Immunotherapy for Pleural Mesothelioma
Long-Term Control in Select Patients: Some patients experience durable responses lasting two years or more—something rarely seen with chemotherapy alone.
Better Tolerability for Some Patients: While side effects can be serious, especially autoimmune-related ones, many patients find immunotherapy easier to tolerate than traditional chemo.
Hope for Hard-to-Treat Subtypes: Immunotherapy offers new hope for patients with sarcomatoid or biphasic histology, who previously had few effective options.
Cost Considerations for Immunotherapy
Immunotherapy drugs are expensive, with total treatment costs often exceeding $100,000. However, asbestos trust funds, legal settlements, and veterans’ benefits often cover these therapies when they are recommended by a treating oncologist. Many drug manufacturers also offer copay assistance or financial aid for eligible patients.
Immunotherapy is not right for every patient, but for many, it has become a life-extending treatment option—and in a few cases, a long-term stabilizer of the disease. As research continues, combination regimens and biomarkers may help predict who will benefit most, ushering in a more personalized era of mesothelioma care.
Other Therapies and Clinical Trials for Pleural Mesothelioma
For patients who have exhausted standard treatments—or who want access to the most cutting-edge care—clinical trials and emerging therapies offer new hope. Researchers are actively exploring novel drug combinations, targeted therapies, and cellular treatments that could reshape how pleural mesothelioma is treated in the coming years.
Anti-VEGF Therapies
Drugs that block vascular endothelial growth factor (VEGF) aim to cut off the tumor’s blood supply, starving it of oxygen and nutrients. Two of the most studied agents in this category are:
Ramucirumab (rah-myoo-SIR-oo-mab), which targets VEGF receptor 2. In a Phase II trial, it was combined with gemcitabine and showed a modest survival benefit, especially as a second-line therapy in patients who had progressed after platinum-based chemo.
Nintedanib (nin-TED-uh-nib), a multi-targeted kinase inhibitor, was evaluated in combination with cisplatin and pemetrexed. While early studies showed promise, a larger Phase III trial failed to improve progression-free survival, and enthusiasm for this regimen has declined.
Overall, anti-angiogenic therapies have shown mixed success in mesothelioma—possibly due to the cancer’s complex blood vessel structure and immune evasion tactics—but they remain under investigation in combination with other drugs. 3
Cellular Therapies and Antibody–Drug Conjugates (ADCs)
Researchers are also exploring more precise ways to attack cancer cells, including cellular therapies and antibody-based treatments:
Anetumab ravtansine (uh-NET-oo-mab rav-TAN-seen) is an antibody–drug conjugate (ADC) that specifically targets mesothelin, a protein often overexpressed in mesothelioma. The antibody delivers a potent chemotherapy agent directly to the tumor cells while sparing most healthy tissue. In early trials, this drug was paired with pembrolizumab (pem-broh-LIZ-oo-mab), an immune checkpoint inhibitor, and showed encouraging results for tumor control and patient safety.
Other investigational ADCs and CAR T-cell therapies (which engineer a patient’s immune cells to attack cancer) are in very early stages but hold long-term promise for highly personalized treatment approaches.
These treatments are not yet FDA-approved for mesothelioma but may be available through clinical trials at academic cancer centers.
Clinical Trials and Precision Medicine
Access to clinical trials is one of the most important opportunities for patients with mesothelioma, especially as new therapies move from research to real-world application. Many trials offer first access to promising treatments that aren’t available anywhere else.
Precision medicine is also playing a growing role. Although mesothelioma doesn’t typically have high mutation rates, rare gene alterations like NTRK or ALK fusions may be detected through molecular profiling. These patients may qualify for targeted therapies already approved for other cancers.
Broad genetic testing (next-generation sequencing) is now recommended in many guidelines for mesothelioma patients, to help identify rare mutations that could open the door to clinical trial enrollment or off-label targeted therapy.
If you or a loved one has pleural mesothelioma, it’s worth asking your doctor about clinical trial options, especially at major cancer centers or mesothelioma specialty clinics. Participating in a trial may offer access to breakthrough treatments—and contributes to future advances that can benefit others as well.
Quality of Life and Symptom Burden for Pleural Mesothelioma
While treatment for pleural mesothelioma can slow disease progression and extend survival, the cancer itself—and its therapies—often have a profound impact on a patient’s quality of life (QoL). Understanding the symptoms and their effect on daily living is an important part of planning care and setting realistic expectations.
Common Symptoms of Pleural Mesothelioma
Most patients experience a combination of physical symptoms that can interfere with daily activities and emotional well-being. The most commonly reported include:
Fatigue: A deep, persistent exhaustion that doesn’t improve with rest. It often limits independence and makes routine tasks feel overwhelming.
Dyspnea (shortness of breath): Caused by fluid buildup (pleural effusion) or tumor growth pressing on the lungs. It may worsen with activity and lead to anxiety or panic.
Chronic cough: Often dry and unrelenting, the cough can disrupt sleep and make speaking or eating uncomfortable.
Chest or shoulder pain: Pain may stem from tumor invasion of the chest wall or nerve involvement. It can be sharp, dull, or persistent, and sometimes requires opioid management.
These symptoms tend to intensify as the disease progresses, especially in the absence of effective treatment. Even patients who respond to therapy may continue to experience some degree of these symptoms.
Hospitalizations and Treatment Side Effects
Roughly 30% to 50% of mesothelioma patients are hospitalized at some point during treatment—whether for symptom management, chemotherapy complications, infections, or surgical recovery. 5 Hospital stays may range from a few days to over a week, depending on the intervention.
Common side effects of treatment include:
Anemia and low blood counts, which worsen fatigue
Nausea and appetite loss, particularly during chemotherapy
Neuropathy (numbness/tingling) from platinum-based drugs like cisplatin
Infusion reactions or autoimmune flare-ups from immunotherapy
While many side effects can be managed with medication or supportive care, they contribute to the overall burden of the disease—especially in older patients or those with other health conditions.
Decline in Quality of Life With Disease Progression
Patient-reported studies show a notable decline in quality of life as mesothelioma progresses, particularly during the transition from first-line treatment to later stages. 5 In one European survey, patients’ EQ-5D scores—a standardized health measure—dropped from a moderate level of 0.615 during initial treatment to 0.497 in second-line care. Visual analog scale (VAS) scores, which capture how patients rate their own health, also declined from 60.8 to 56.1.
These scores are widely used tools to measure how patients perceive their overall health and daily functioning. The EQ-5D score ranges from 0 (equivalent to death) to 1 (perfect health) and is based on five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. A drop from 0.615 to 0.497 indicates a meaningful decline in multiple aspects of day-to-day life. The Visual Analog Scale (VAS) asks patients to rate their own health on a scale from 0 to 100, with higher numbers reflecting better perceived well-being. Even small decreases in these scores can reflect increased pain, fatigue, or emotional distress—offering valuable insight into the lived experience of patients with progressing disease.
These numbers reflect not only worsening physical symptoms, but also the emotional and social toll of the disease. Many patients require daily assistance from caregivers, and both patients and loved ones report increasing levels of psychological stress as the disease advances. 5
Addressing the Burden
Palliative care services—including pain management, counseling, physical therapy, and spiritual support—can make a meaningful difference. Integrating these services early, even during active treatment, has been shown to improve comfort and emotional well-being without shortening survival.
Mesothelioma care isn't just about fighting the disease—it's also about preserving dignity, comfort, and quality of life for as long as possible.
Cost of Care and Financial Considerations for Pleural Mesothelioma
The financial burden of mesothelioma treatment can be overwhelming. Even with insurance, the costs of hospitalization, medications, and long-term care add up quickly—especially for a cancer that requires highly specialized treatment. For many patients, understanding the potential costs is an essential part of planning for care and exploring all available support options.
Hospitalization and Treatment Costs
The average cost of a single hospital stay for mesothelioma in the United States is approximately $25,000, though this figure can vary based on region, hospital type, and the complexity of care. 2 Patients undergoing major surgery—like pleurectomy/decortication or extrapleural pneumonectomy—often face even higher expenses, especially when intensive care or post-operative complications are involved.
Treatment type also plays a major role in cost:
Chemotherapy drugs like pemetrexed and cisplatin can cost upwards of $38,000 for a full course.
Adding bevacizumab, often used in unresectable cases, increases drug costs to nearly $88,000.
Immunotherapy agents such as nivolumab or ipilimumab can cost over $100,000 per year of treatment.
When surgery, chemotherapy, and radiation are combined—a common strategy for patients with resectable disease—the lifetime cost of care can easily exceed $100,000, even before factoring in indirect costs.
Hidden Costs That Add Up
In addition to direct medical expenses, mesothelioma patients and their families face a range of “hidden costs” that may not be fully covered by insurance:
Maintenance therapy: Some patients continue treatment for months or years to keep the cancer from returning, incurring ongoing drug and infusion center fees.
Side-effect management: Anti-nausea medications, pain control, oxygen therapy, and nutritional support all contribute to out-of-pocket costs.
Travel and lodging: Because mesothelioma specialists are often located at academic cancer centers, patients may need to travel across state lines, sometimes for weeks at a time.
Lost income: Patients and caregivers may miss work—or stop working entirely—due to treatment schedules or physical limitations.
Legal and Financial Support Options
Fortunately, there are financial resources available to help ease the burden:
Many patients qualify for compensation through asbestos trust funds, which were established by bankrupt companies responsible for exposing workers to asbestos.
Those exposed during military service may be eligible for VA benefits, including medical care and monthly compensation.
In addition to trust claims, lawsuits and settlements can provide significant funds to cover past and future medical costs.
Pharmaceutical companies often offer copay assistance programs, especially for expensive immunotherapies.
If you’ve been diagnosed with mesothelioma, it's worth exploring your legal options. You may be entitled to financial compensation that can cover not just treatment—but also travel, lost income, and caregiver support.
How We Can Help Families Affected by Pleural Mesothelioma
A mesothelioma diagnosis is overwhelming—but you don’t have to face it alone. Our law firm's founder was personally affected by asbestos-related cancer, and we’ve spent years helping families get the care and compensation they deserve. We understand the emotional and financial strain this disease brings, and our mission is to lift as much of that burden as we can.
Covering the Cost of Treatment
We help clients access compensation from a range of sources, including:
Asbestos Trust Funds: Many companies that exposed workers to asbestos were forced to create trust funds when they filed for bankruptcy. These trusts are still paying out claims today. In most cases, if your diagnosis is linked to asbestos—even decades ago—you’re eligible to file a claim.
Lawsuits Against Responsible Companies: If the companies that exposed you to asbestos are still operating, you may have the right to bring a legal claim against them. These lawsuits often result in confidential settlements and can be filed without ever going to court.
Social Security Disability Benefits (SSD/SSDI): If you’ve been diagnosed with pleural mesothelioma, you may qualify for fast-tracked Social Security Disability benefits through the Compassionate Allowances program. The Social Security Administration (SSA) recognizes mesothelioma as a severe condition, which means your application is often processed and approved in weeks instead of months. These benefits can provide monthly income and, in some cases, early access to Medicare coverage—even if you're not yet 65. We help clients prepare strong applications, avoid common mistakes, and navigate appeals if needed, so they can start receiving support as quickly as possible.
VA Claims for Veterans: If you were exposed to asbestos during military service, we can help you pursue benefits through the Department of Veterans Affairs. Many veterans are eligible for monthly compensation, treatment at VA hospitals, or both.
Learn more about the legal options available to families affected by pleural mesothelioma.
Why Our Clients Rely Upon Us to Help Their Families
We understand the disease. Our founding attorney lost multiple family members to asbestos-related cancer—including his grandfather, father, and grandmother. He knows firsthand what it feels like to watch someone you love fight this illness. That experience shaped how we practice law: with compassion, urgency, and a deep respect for what our clients are going through. This isn’t just our work—it’s personal. That’s why we’ve built one of the most comprehensive asbestos litigation knowledge bases in the country, including millions of pages of corporate documents, scientific studies, court filings, and exposure records. We know this fight from every angle—and we bring that knowledge to every client we serve.
We take care of the paperwork. When you're dealing with a cancer diagnosis, the last thing you should have to worry about is gathering old job records or medical files. We handle all of it—from filing claims to tracking down exposure evidence. Our team works with medical experts, industrial hygienists, and investigators to reconstruct your exposure history, even if it happened decades ago. We know where asbestos was used, who made it, and how to build the strongest possible case—because we’ve done it thousands of times before. You focus on your care; we’ll take care of the rest.
We work nationwide. Whether you were exposed on a Navy ship, in a petrochemical plant, at a construction site, or in an auto shop—we can help, no matter where you live now. We have offices in California, Washington, Texas, and Arizona, and we routinely represent clients across the country. With our top-tier virtual technology, we make it easy to meet with you by phone or video. And if you prefer a face-to-face visit, we’ll travel to you—at no cost. Our goal is to make the legal process simple, convenient, and accessible to every mesothelioma family we serve.
No upfront costs. You never pay us out-of-pocket. We front all legal costs ourselves, covering everything from expert witness fees to court filings. You owe us nothing unless we recover money for you. That’s how confident we are in our ability to win. Over the years, we’ve recovered more than $400 million for families affected by asbestos-related diseases like mesothelioma. We take on all the risk—so you can focus on healing, knowing we’re fighting for the financial support your family deserves.
A Path Forward
Your medical team is fighting for your health. Let us fight for your financial future and for your family's legacy. We’ll walk you through your legal options, help determine which trust funds or companies are responsible, and take swift action so you can focus on your care—not your bills.
Contact us today for a free consultation. There’s no obligation, and every conversation is 100% confidential.
References
Jain M, Crites MK, Rich P, Bajantri B. Malignant Pleural Mesothelioma: A Comprehensive Review. J Clin Med. 2024;13(19):5837. doi:10.3390/jcm13195837
Borrelli E, Babcock Z, Kogut S. Costs of medical care for mesothelioma. Rare Tumors. 2019;11:2036361319863498. doi:10.1177/2036361319863498
Imai H. Current drug therapy for pleural mesothelioma. Respir Investig. 2025;63(3):200–209. doi:10.1016/j.resinv.2024.12.017
Chiec L, Bruno DS. Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies. Int J Mol Sci. 2024;25(19):10861. doi:10.3390/ijms251910861
Cedres S, Calvete J, Taylor-Stokes G, et al. Treatment patterns and humanistic burden of malignant pleural mesothelioma in Spain. Clin Transl Oncol. 2025;27:213–222. doi:10.1007/s12094-024-03591-5